Cas:28718-78-7 5-bromo-2-(4-bromophenyl)-1-benzofuran manufacturer & supplier

We serve Chemical Name:5-bromo-2-(4-bromophenyl)-1-benzofuran CAS:28718-78-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-bromo-2-(4-bromophenyl)-1-benzofuran

Chemical Name:5-bromo-2-(4-bromophenyl)-1-benzofuran
CAS.NO:28718-78-7
Synonyms:ben739
Molecular Formula:C14H8Br2O
Molecular Weight:352.02100
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:13.14000
Exact Mass:349.89400
LogP:5.62480

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like ben739 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ben739 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ben739 Use and application,ben739 technical grade,usp/ep/jp grade.


Related News: This also includes its anti-tau pipeline, with the FDA’s approval having “implications for AD programmes targeting Tau,” according to Jefferies. 5-bromo-2-(4-bromophenyl)-1-benzofuran manufacturer At present, Linhai, Zhejiang Province, has established a national chemical raw material base in Zhejiang Province, which is the earliest and largest gathering area of ??domestic chemical raw material medicines and pharmaceutical intermediate industries. 5-bromo-2-(4-bromophenyl)-1-benzofuran supplier This also includes its anti-tau pipeline, with the FDA’s approval having “implications for AD programmes targeting Tau,” according to Jefferies. 5-bromo-2-(4-bromophenyl)-1-benzofuran vendor From the perspective of product structure, the varieties of these enterprises are mainly concentrated in vitamins, antipyretics and analgesics, antibiotics and corticosteroids (ie bulk drug substances). 5-bromo-2-(4-bromophenyl)-1-benzofuran factory This also includes its anti-tau pipeline, with the FDA’s approval having “implications for AD programmes targeting Tau,” according to Jefferies.